MANSFIELD, Mass., Aug. 30 /PRNewswire/ -- PrimeraDx today announced that Matthew F. McManus, M.D., Ph.D., has been appointed President and Chief Executive Officer effective immediately. Dr. McManus has also been appointed to the Company's Board of Directors.
"We are delighted to have Matthew join PrimeraDx during this exciting time in the Company's evolution, as we prepare to launch the first products based on our unique platform for high-multiplex quantitative PCR, which we believe has 'game-changing' potential for molecular diagnostics," stated interim CEO and Board Member Vincent J. Miles, Ph.D., of Abingworth. "With his recent experience running one of the country's major reference laboratories, and his training as a physician-scientist, Matthew brings a unique combination of customer perspective, leadership skills, operational expertise and scientific understanding to the Company."
Dr. McManus joined PrimeraDx in August 2010 from his prior position as Head of Cleveland Clinic Laboratories (CCL) and Chief Operating Officer of the Pathology and Laboratory Medicine Institute. In his three years in Cleveland he successfully expanded the Clinic's reference laboratory services and secured funding for construction of a major new laboratory facility. Prior to leading CCL, he was the Medical Scientist for the Novartis Institutes for Biomedical Research Drug Discovery Incubator, where he helped found the External Fast Follower group. He has also worked at McKinsey & Company, consulting for diagnostics, device and other health care clients, and at Procter & Gamble in sales and marketing. He received his MD and Ph.D. from the University of Pennsylvania School of Medicine, his MBA from Boston College, and his BA from the College of the Holy Cross.
"When I learned of PrimeraDx's technology platform I immediately recognized how important it can be in many different areas of molecular diagnostics and clinical practice, and I am thrilled by the opportunity to lead the Company as we launch our first products and broaden the applications of the platform to address a variety of high-impact clinical decisions," commented Dr. McManus. "Our technologies will have direct and significant benefits for patients and caregivers, and represent a huge leap forward in both ease of use and quality for laboratories."
CONTACT: Ted Myles, Chief Financial Officer, 508-618-2349, email@example.com